glp-1 autoimmune Association between diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study GLP-1 Obesity Drugs May Lower

Pronounced economic benefits of GLP-1RA therapy among those with prior CVDs or CKDs support rational treatment decisions and optimal healthcare resource allocation for these patients [43]

Sung PS, Yeh CC, Wang LC, et al

Think of it like a cup of coffee: the less water you use, the stronger the smell and taste

The FDAs position is that compounders cant mass-produce copycat GLP-1s now that shortages are over

the Core Research for Evolutional Science and Technology from the JST (to Masayuki Yamamoto and Hozumi Motohashi)

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH